Focusing on the global pharmaceutical industry trends, multinational pharmaceutical companies are keen to "dismantle"

In the month to 2020, at least three pharmaceutical giants announced spin-off plans: Mercedon, GSK and Sanofi.
Among them, Mercedon announced that it would continue to retain its oncology, in-hospital products, vaccines and biopharmaceity businesses, while setting up a new company and independently listing women's health products, mature products and biosynthic products, which is expected to be completed in the first half of 2021; Sanofi plans to split the company into two entities over the next two years, one focusing on pharmaceuticals and drug development and the other on consumer health, and Sanofi has announced that it will merge six API production sites in Europe to create an independent API company.
the global pharmaceutical industry over the past few years, mergers and acquisitions, divestitures are common business operations, and divestitures are becoming a hot event for multinational pharmaceutical companies.
statistics show that in the past 10 years, at least 12 of the world's largest drugmakers, including AstraZeneta, Merck and so on, and after the split, 39 subsidiaries on the road to independent development.
, how are these broken-up companies doing? Statistically, 10 of the 39 companies are listed, eight are still private and 11 have been acquired, with the rest either bankrupt or flat.
of the companies that have successfully listed on the market should be the three companies that pharmaceutical giant AstraZeneta has split up: Viela Bio, Albireo and Entasis.
In February 2018, AstraZenecom announced that it was splitting up Viela Bio into an independent biotech company focused on developing innovative therapies for autoimmune and severe inflammatory diseases;
Albireo left AstraZenecon in 2008 to focus on the development and potential commercialization of new bile acid regulators, and Entasis was founded in 2015 to discover and develop new antibacterial products with AstraZenecon's start-up capital and some of its research and development platform mandates.
the two spin-off subsidiaries are also listed on NASDAQ and have Clinical Phase III products.
can say that AstraZeneta's three subsidiaries have performed quite well since the spin-off.
also successful spin-offs include Pfizer's SpringWorks in 2017 and Shuten in 2013.
was established in September 2017 and listed on NASDAQ on September 13, 2019, raising $132 million, while the former was listed on the New York Stock Exchange on February 1, 2013, with a 7% increase in revenue of $6.3 billion and net income of $1.5 billion.
, however, there are subsidiaries that have survived relatively briefly after being "dismantled", either acquired or inactive.
, for example, in August 2016, Yan Jian announced the spin-off of its haemophilia business and the formation of an independent new company called Bioverativ, focusing on neuropathy such as multiple sclerosis and Alzheimer's disease.
, on january 12, 2017, officially landed on the NASDAQ Stock Exchange.
but Bioverativ's existence was short-lived, and after only a year of independent listing, Sanofi bought all of its public offerings for $11.6 billion.
It can be seen that for pharmaceutical companies, in the context of fierce global market competition, policy overlays, splitting is a strategy to spin off the non-core parts, but for the new companies that are being spun off, independent development is not an easy thing, may be revitalized, may also be buried.